{
  "title": "Paper_711",
  "abstract": "pmc Sci Rep Sci Rep 1579 scirep Scientific Reports 2045-2322 Nature Publishing Group PMC12479950 PMC12479950.1 12479950 12479950 41022839 10.1038/s41598-024-82656-5 82656 1 Article Multi-step organic synthesis, cytotoxicity, and molecular docking of new N N N Ahmed Abdullah A. 1 El-All Mahmoud M. Abd 1 El-Hallouty Salwa M. 2 Elshahid Zeinab A. 3 http://orcid.org/0000-0001-5570-1427 Eliwa Essam M. essameliwa85@azhar.edu.eg 1 1 https://ror.org/05fnp1145 grid.411303.4 0000 0001 2155 6022 Chemistry Department, Faculty of Science (Boys), Al-Azhar University, 2 https://ror.org/02n85j827 grid.419725.c 0000 0001 2151 8157 Drug Bioassay-Cell Culture Laboratory, Pharmacognosy Department, Pharmaceutical and Drug Industries Division, National Research Centre, 3 https://ror.org/02n85j827 grid.419725.c 0000 0001 2151 8157 Chemistry of Natural and Microbial Products, Pharmaceutical Drug Industry and Research Institute, National Research Center, 29 9 2025 2025 15 478255 33340 6 8 2024 6 12 2024 29 09 2025 01 10 2025 01 10 2025 © The Author(s) 2024 2024 https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access http://creativecommons.org/licenses/by-nc-nd/4.0/ Building on our previous research on edaravone-derived bioactive small molecules, the precursors 2–5 1 2 N N 6a b N N 7a b 6a b 2 7a b via 2 via 4 50 4 4 8 4 Supplementary Information The online version contains supplementary material available at 10.1038/s41598-024-82656-5. Keywords Edaravone N N N MTT RIPK3 Subject terms Chemical biology Chemistry pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes issue-copyright-statement © Springer Nature Limited 2025 Introduction Diversity-oriented synthesis (DOS) is a paradigm for generating structurally diverse natural product-like and/or drug-like small molecules as probes to examine their biological activities. The investigation of bioactivities may be useful in lead candidate identification for drug discovery and development or can facilitate the identification of novel molecules with the desired physiochemical features and drug-like nature 1 4 via 5 6 Pyrazolone nucleus is classically constructed by Knorr condensation reaction of β 7 8 11 via 12 Importantly, the N 1 13 14 15 16 17 18 12 19 12 20 Bioactive N 21 24 N S. aureus B. subtilis S. aureus B. subtilis 25 8 N N via 26 27 Continuing our research on bioactive small molecules based on N 28 29 fragment diversity N N N N  Fig. 1 Chemical structures of marketed drugs and investigational drug candidates containing the N Results and discussion Design strategy Motivated by the MTT-cytotoxicity [IC 50 N N 8 N N N N 2 1–5 6a–7b chemical synthesis 1 via 30 31 30 6a 6b 7b The flexibility is defined by the number of rotatable bonds (nRot) that ranges from 4 to 10 (optimal: 0 ~ 11 ≠), thus all the compounds could be flexible, considering the number of rings that are between 3 and 7 ( 6a 32 n 33 1 3 5 6a 6b  Fig. 2 Design strategy of target compounds.  Table 1 Physicochemical properties, lipophilicity, and drug-likeness nature of the target compounds 1–7b a b c d e f n g h i j 30 Organic synthesis The multi-step diversity-oriented S, N-heterocyclization routes that are required to synthesize the chemical precursors 1–5 6a–7b 1 N 2 8 2 3–5 1 p 1 3 δ H δ H 3 3 δ H 3 3 13 δ C δ C 3 + m/z 3 2 −1 The key NMR signals of 4 3 δ H 13 δ C 1 4 δ H 1 p 5 δ H 2–4 2 δ H δ c δ C δ C 13 5 −1 5 + m/z Afterwards, we focused on the preparation of the target compounds 6a–7b 3 2 N 34 via 2 N N 6a b 1 6a b N 6a b 2 6a b δ H 2 δ H δ H 6b 6a 6a b –1 35 6a b via m/z + + Among thioether synthesis protocols, 1,4-conjugate thia-Michael addition is an extremely useful technique and an atom-efficient chemical process to access thioethers 36 2 N N 7a b 1 7a b δ H δ H 37 40 7a δ H 7b δ H 2 3 7a b −1 7a b + m/z Mechanistically, the neutral nucleophilic thiol tautomer of 2 A B E 1 Z 2 E A via 7a/7b 3 7a 7b 1 δ H δ H 37 40 Mnova δ H δ H 7a A B 39  Fig. 3 The proposed mechanism for formation of 7a A B Anticancer activity In vitro cytotoxicity activity via cellular bioassay The MTT cellular bioassay 41 1–7 2 4 6a 7b 50 4 50 4 8  Table 2 In vitro cytotoxicity activity of the target compounds 1–7 Compounds IC 50 a Hos A549 HCT-116  1 > 50 > 50 > 100  2 > 100 > 100 > 50  3 > 100 > 100 > 100  4 39.9 ± 0.07 20.4 ± 0.55 7.3 ± 0.47  5 > 100 > 100 > 100  6a 60.1 ± 0.06 > 100 > 100  6b > 100 > 100 > 100  7a > 50 > 100 > 100  7b 47.6 ± 0.15 > 100 > 100 Lead cpd b 5.8 ± 0.10 10.9 ± 0.11 > 100 Doxorubicin c 0.03 ± 0.03 0.087 ± 0.09 2.2 ± 3.10 DMSO d – – – a 50 b 8 c d In vitro pRIPK3 kinase concentration determination via ELISA technique After that, following the procedure mentioned in the user manual of the enzyme-linked immunosorbent assay (ELISA) kit, the pRIPK3 kinase concentration in the A549 non-small lung cancer cell line 8 42 43 4 4 50 4 2 3 4 8 see 2 39  Table 3 Effect of the active molecule 4 Compounds Concentration (pg/mL) a pRIPK3 in A549  4 2.97 ± 0.010 Lead cpd b 2.89 ± 0.005 DMSO c 2.93 ± 0.010 a b 8 c Molecular docking The i 44 45 4 4 N 4 van der Waals 2 4 see 2 4 8 4  Fig. 4 ( a b c 4 4 Materials and methods Materials and instrumental techniques See the supporting information file. Chemical synthesis Synthesis of compounds 1 2 See our previous study 8 General procedure for the synthesis of the chemical precursors 3–5 As a miniscale synthesis, a powder funnel was used to add 1 p 3–5 2-(1-(4-((3-Methyl-5-oxo-1-phenyl-1,5-dihydro-4 H-pyrazol-4-ylidene)methyl)amino)phenyl)ethylidene)-hydrazine-1-carbothioamide ( 3 Yellow amorphous solid; 85% yield; mp 260–262 °C; mid FT-IR (KBr, ν/cm −1 – 2 1 d 6 J 13 d 6 20 20 6 m/z + 4-Methyl-N’-(1-(4-(((3-methyl-5-oxo-1-phenyl-1,5-dihydro-4 H-pyrazol-4-ylidene)methyl)amino)phenyl)-ethylidene)benzenesulfonohydrazide ( 4 Yellow amorphous solid; 89% yield; mp 226–228 °C; mid FT-IR (KBr, ν/cm −1 – – – 1 d 6 J J 13 d 6 26 25 5 3 m/z + 2-Cyano-N’-(1-(4-(((3-methyl-5-oxo-1-phenyl-1,5-dihydro-4 H-pyrazol-4-ylidene)methyl)amino)phenyl)-ethylidene)acetohydrazide ( 5 Yellow amorphous solid; 89% yield; mp 222–225 °C; mid FT-IR (KBr, ν/cm −1 – – – 1 d 6 J J J J J J J 13 d 6 22 20 6 2 m/z + General procedure for the synthesis of N-phenylpyrazolone-N-benzylthiazole hybrids bearing an azo phenyl fragment ( 6a b Setting up miniscale refluxing conditions, the chemical precursor 2 3 6a b 4-(((4-(1-((3-Benzyl-4-phenyl-5-(phenyldiazenyl)thiazol-2(3 H)-ylidene)hydrazineylidene)ethyl)phenyl)-amino)methylene)−5-methyl-2-phenyl-2,4-dihydro-3 H-pyrazol-3-one ( 6a Deep red amorphous solid; 83% yield; mp 177–180 °C; mid FT-IR (KBr, ν/cm-1) 3410 (N – – – 1 d 6 J J J J J J J J 13 d 6 41 34 8 + 4-(((4-(1-((3-Benzyl-5-((4-chlorophenyl)diazenyl)−4-methylthiazol-2(3 H)-ylidene)hydrazineylidene)ethyl)-phenyl)amino)methylene)−5-methyl-2-phenyl-2,4-dihydro-3 H-pyrazol-3-one ( 6b Deep brown amorphous solid; 88% yield; mp 209–212 °C; mid FT-IR (KBr, ν/cm-1) 3221 (N – – – 1 d 6 J J J J J 13 d 6 36 31 8 m/z + General procedure for the synthesis of N-phenylpyrazolone-N-benzyl-4-thiazolone hybrids linked to an acrylate unit ( 7a b To an oven-dry 100 mL round-bottomed flask charged with a magnetic stir bar, 0.96 g of N 2 7a b Methyl 2-(3-benzyl-2-((1-(4-(((3-methyl-5-oxo-1-phenyl-1,5-dihydro-4 H-pyrazol-4-ylidene)methyl)amino)-phenyl)ethylidene)hydrazineylidene)−4-oxothiazolidin-5-ylidene)acetate ( 7a Yellow amorphous solid; 81% yield; mp 222–225 °C; mid FT-IR (KBr, ν/cm-1) 3432 (N–H stretching), 3070 (aromatic C – 1 d 6 J J J J J J J 13 d 6 32 28 6 4 m/z + Ethyl 2-(3-benzyl-2-((1-(4-(((3-methyl-5-oxo-1-phenyl-1,5-dihydro-4 H-pyrazol-4-ylidene)methyl)amino)-phenyl)ethylidene)hydrazineylidene)−4-oxothiazolidin-5-ylidene)acetate ( 7b Yellow amorphous solid; 86% yield; mp 164–167 °C; mid FT-IR (KBr, ν/cm-1) 3397 (N – – – 1 d 6 J J J J J J J J J J 13 d 6 33 30 6 4 m/z + Anticancer activity In vitro 2D model (monolayer) cytotoxicity activity via cellular MTT bioassay. In vitro pRIPK3 kinase concentration determination via ELISA technique. In silico molecular docking DFT calculations See the supporting information file. Conclusions In summary, two thiosemicarbazones ( 2 3 4 5 1 via 2 N N 6a b N N 7a b 6a b via 2 7a b 2 7a 7b 4 50 4 50 4 4 8 4 N Electronic supplementary material Below is the link to the electronic supplementary material.  Supplementary Material 1 Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Acknowledgements The authors wish to express deep thanks to the Chemistry Department, Faculty of Science, Al-Azhar University, Egypt, for the equipment and chemical materials. Author contributions “Essam Eliwa wrote the main manuscript; Abdullah A. Ahmed and Mahmoud M. Abd El-All did the organic synthesis work; Salwa M. El-Hallouty and Zeinab A. Elshahid did the biological evaluation. All authors reviewed the manuscript.” Data availability Spectroscopic NMR and IR, as well as spectrometry mass data that support the findings of our study, are provided in the supplementary information file. Declarations Competing interests The authors declare no competing interests. References 1. Hudson L Diversity-oriented synthesis encoded by deoxyoligonucleotides Nat. Commun. 2023 14 4930 10.1038/s41467-023-40575-5 37582753 PMC10427684 Hudson, L. et al. Diversity-oriented synthesis encoded by deoxyoligonucleotides. Nat. Commun. 14 37582753 10.1038/s41467-023-40575-5 PMC10427684 2. Spandl RJ Díaz-Gavilán M O’Connell KMG Thomas GL Spring DR Diversity-oriented synthesis Chem. Rec 2008 8 129 142 10.1002/tcr.20144 18563806 Spandl, R. J., Díaz-Gavilán, M., O’Connell, K. M. G., Thomas, G. L. & Spring, D. R. Diversity-oriented synthesis. Chem. Rec 8 18563806 10.1002/tcr.20144 3. Galloway WRJD Isidro-Llobet A Spring DR Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules Nat. Commun. 2010 1 80 10.1038/ncomms1081 20865796 Galloway, W. R. J. D., Isidro-Llobet, A. & Spring, D. R. Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. Nat. Commun. 1 20865796 10.1038/ncomms1081 4. Lenci E Innocenti R Menchi G Trabocchi A Diversity-oriented synthesis and chemoinformatic analysis of the Molecular Diversity of sp3-Rich Morpholine Peptidomimetics Front. Chem. 2018 6 522 10.3389/fchem.2018.00522 30425982 PMC6218424 Lenci, E., Innocenti, R., Menchi, G. & Trabocchi, A. Diversity-oriented synthesis and chemoinformatic analysis of the Molecular Diversity of sp3-Rich Morpholine Peptidomimetics. Front. Chem. 6 30425982 10.3389/fchem.2018.00522 PMC6218424 5. Phiri, C. M. & Saxena, A. Multi-step organic synthesis: A review of some synthetic routes and applications. AIP Conf. Proc. 6. Mechelke MF Advanced Organic Chemistry Laboratory: a Multistep synthesis toward the Preparation of a small Library of Antituberculosis compounds J. Chem. Educ. 2022 99 3265 3271 10.1021/acs.jchemed.2c00508 Mechelke, M. F. Advanced Organic Chemistry Laboratory: a Multistep synthesis toward the Preparation of a small Library of Antituberculosis compounds. J. Chem. Educ. 99 7. Hamama S El-Gohary WG Kuhnert H Zoorob H Chemistry of Pyrazolinones and their applications Curr. Org. Chem. 2012 16 373 399 10.2174/138527212799499921 Hamama, S., El-Gohary, W. G., Kuhnert, H., Zoorob, H. & N. & Chemistry of Pyrazolinones and their applications. Curr. Org. Chem. 16 8. Ahmed AA El-All MMA El‐Hallouty SM Elshahid ZA Eliwa EM New edaravone analogs incorporated with N ‐benzylthiazole moiety: multistep chemical synthesis, in vitro cytotoxicity with pRIPK3 inhibitory activities, and molecular docking J. Heterocycl. Chem. 2024 61 1349 1363 10.1002/jhet.4858 Ahmed, A. A., El-All, M. M. A., El‐Hallouty, S. M., Elshahid, Z. A. & Eliwa, E. M. New edaravone analogs incorporated with N ‐benzylthiazole moiety: multistep chemical synthesis, in vitro cytotoxicity with pRIPK3 inhibitory activities, and molecular docking. J. Heterocycl. Chem. 61 9. Xu Y Shen M Zhang X Fan X Selective synthesis of Pyrazolo[1,2- a ]pyrazolones and 2-Acylindoles via Rh(III)-Catalyzed tunable redox-neutral coupling of 1-Phenylpyrazolidinones with Alkynyl Cyclobutanols Org. Lett. 2020 22 4697 4702 10.1021/acs.orglett.0c01475 32463683 Xu, Y., Shen, M., Zhang, X. & Fan, X. Selective synthesis of Pyrazolo[1,2- a ]pyrazolones and 2-Acylindoles via Rh(III)-Catalyzed tunable redox-neutral coupling of 1-Phenylpyrazolidinones with Alkynyl Cyclobutanols. Org. Lett. 22 32463683 10.1021/acs.orglett.0c01475 10. Xie X Xiang L Peng C Han B Catalytic asymmetric synthesis of Spiropyrazolones and their application in Medicinal Chemistry Chem. Rec 2019 19 2209 2235 10.1002/tcr.201800199 30821425 Xie, X., Xiang, L., Peng, C. & Han, B. Catalytic asymmetric synthesis of Spiropyrazolones and their application in Medicinal Chemistry. Chem. Rec 19 30821425 10.1002/tcr.201800199 11. Casas J Garcia-Tasende M Sanchez A Sordo J Touceda A Coordination modes of 5-pyrazolones: a solid-state overview Coord. Chem. Rev. 2007 251 1561 1589 10.1016/j.ccr.2007.02.010 Casas, J., Garcia-Tasende, M., Sanchez, A., Sordo, J. & Touceda, A. Coordination modes of 5-pyrazolones: a solid-state overview. Coord. Chem. Rev. 251 12. Zhao Z Pyrazolone structural motif in medicinal chemistry: retrospect and prospect Eur. J. Med. Chem. 2020 186 111893 10.1016/j.ejmech.2019.111893 31761383 PMC7115706 Zhao, Z. et al. Pyrazolone structural motif in medicinal chemistry: retrospect and prospect. Eur. J. Med. Chem. 186 31761383 10.1016/j.ejmech.2019.111893 PMC7115706 13. Lapchak PA A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin. Pharmacother 2010 11 1753 1763 10.1517/14656566.2010.493558 20491547 PMC2891515 Lapchak, P. A. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin. Pharmacother 11 20491547 10.1517/14656566.2010.493558 PMC2891515 14. Küçükgüzel ŞG Şenkardeş S Recent advances in bioactive pyrazoles Eur. J. Med. Chem. 2015 97 786 815 10.1016/j.ejmech.2014.11.059 25555743 Küçükgüzel, Ş. G. & Şenkardeş, S. Recent advances in bioactive pyrazoles. Eur. J. Med. Chem. 97 25555743 10.1016/j.ejmech.2014.11.059 15. Meiattini F Prencipe L Bardelli F Giannini G Tarli P The 4-hydroxybenzoate/4-aminophenazone chromogenic system used in the enzymic determination of serum cholesterol Clin. Chem. 1978 24 2161 2165 10.1093/clinchem/24.12.2161 719864 Meiattini, F., Prencipe, L., Bardelli, F., Giannini, G. & Tarli, P. The 4-hydroxybenzoate/4-aminophenazone chromogenic system used in the enzymic determination of serum cholesterol. Clin. Chem. 24 719864 16. Kötter T Metamizole-Associated adverse events: a systematic review and Meta-analysis PLoS One 2015 10 e0122918 10.1371/journal.pone.0122918 25875821 PMC4405027 Kötter, T. et al. Metamizole-Associated adverse events: a systematic review and Meta-analysis. PLoS One 10 25875821 10.1371/journal.pone.0122918 PMC4405027 17. Desmond R Townsley DM Dunbar C Young NS Eltrombopag in Aplastic Anemia Semin Hematol. 2015 52 31 37 10.1053/j.seminhematol.2014.10.002 25578417 PMC4293077 Desmond, R., Townsley, D. M., Dunbar, C. & Young, N. S. Eltrombopag in Aplastic Anemia. Semin Hematol. 52 25578417 10.1053/j.seminhematol.2014.10.002 PMC4293077 18. Townsley DM Eltrombopag added to Standard Immunosuppression for aplastic Anemia N Engl. J. Med. 2017 376 1540 1550 10.1056/NEJMoa1613878 28423296 PMC5548296 Townsley, D. M. et al. Eltrombopag added to Standard Immunosuppression for aplastic Anemia. N Engl. J. Med. 376 28423296 10.1056/NEJMoa1613878 PMC5548296 19. Akyel A Alsancak Y Yayla Ç Şahinarslan A Özdemir M Acute inferior myocardial infarction with low atrial rhythm due to propyphenazone: Kounis syndrome Int. J. Cardiol. 2011 148 352 353 10.1016/j.ijcard.2010.05.038 20541820 Akyel, A., Alsancak, Y., Yayla, Ç., Şahinarslan, A. & Özdemir, M. Acute inferior myocardial infarction with low atrial rhythm due to propyphenazone: Kounis syndrome. Int. J. Cardiol. 148 20541820 10.1016/j.ijcard.2010.05.038 20. Hart FD Boardman PL Trial of Nifenazone (‘Thylin’) BMJ 1964 1 1553 1554 10.1136/bmj.1.5397.1553 14133613 PMC1814611 Hart, F. D. & Boardman, P. L. Trial of Nifenazone (‘Thylin’). BMJ 1 14133613 10.1136/bmj.1.5397.1553 PMC1814611 21. Ashour GRS Synthesis, modeling, and biological studies of new thiazole-pyrazole analogues as anticancer agents J. Saudi Chem. Soc. 2023 27 101669 10.1016/j.jscs.2023.101669 Ashour, G. R. S. et al. Synthesis, modeling, and biological studies of new thiazole-pyrazole analogues as anticancer agents. J. Saudi Chem. Soc. 27 22. Salem ME Mahrous EM Ragab EA Nafie MS Dawood KM Synthesis of novel mono- and bis-pyrazolylthiazole derivatives as anti-liver cancer agents through EGFR/HER2 target inhibition BMC Chem. 2023 17 51 10.1186/s13065-023-00921-6 37291635 PMC10251674 Salem, M. E., Mahrous, E. M., Ragab, E. A., Nafie, M. S. & Dawood, K. M. Synthesis of novel mono- and bis-pyrazolylthiazole derivatives as anti-liver cancer agents through EGFR/HER2 target inhibition. BMC Chem. 17 37291635 10.1186/s13065-023-00921-6 PMC10251674 23. Nandurkar Y Shinde A Bhoye MR Jagadale S Mhaske PC Synthesis and Biological Screening of New 2-(5-Aryl-1-phenyl-1 H -pyrazol-3-yl)-4-aryl thiazole derivatives as potential Antimicrobial agents ACS Omega 2023 8 8743 8754 10.1021/acsomega.2c08137 36910954 PMC9996765 Nandurkar, Y., Shinde, A., Bhoye, M. R., Jagadale, S. & Mhaske, P. C. Synthesis and Biological Screening of New 2-(5-Aryl-1-phenyl-1 H -pyrazol-3-yl)-4-aryl thiazole derivatives as potential Antimicrobial agents. ACS Omega 8 36910954 10.1021/acsomega.2c08137 PMC9996765 24. Metwally NH El-Desoky EA Novel Thiopyrano[2,3- d ]thiazole-pyrazole hybrids as potential Nonsulfonamide Human Carbonic anhydrase IX and XII inhibitors: design, synthesis, and biochemical studies ACS Omega 2023 8 5571 5592 10.1021/acsomega.2c06954 36816682 PMC9933482 Metwally, N. H. & El-Desoky, E. A. Novel Thiopyrano[2,3- d ]thiazole-pyrazole hybrids as potential Nonsulfonamide Human Carbonic anhydrase IX and XII inhibitors: design, synthesis, and biochemical studies. ACS Omega 8 36816682 10.1021/acsomega.2c06954 PMC9933482 25. Abu-Melha S Molecular modeling and docking studies of new antimicrobial antipyrine-thiazole hybrids Arab. J. Chem. 2022 15 103898 10.1016/j.arabjc.2022.103898 Abu-Melha, S. Molecular modeling and docking studies of new antimicrobial antipyrine-thiazole hybrids. Arab. J. Chem. 15 26. Martens S Hofmans S Declercq W Augustyns K Vandenabeele P Inhibitors targeting RIPK1/RIPK3: old and new drugs Trends Pharmacol. Sci. 2020 41 209 224 10.1016/j.tips.2020.01.002 32035657 Martens, S., Hofmans, S., Declercq, W., Augustyns, K. & Vandenabeele, P. Inhibitors targeting RIPK1/RIPK3: old and new drugs. Trends Pharmacol. Sci. 41 32035657 10.1016/j.tips.2020.01.002 27. Moriwaki K Chan FKM Regulation of RIPK3- and RHIM-dependent necroptosis by the Proteasome J. Biol. Chem. 2016 291 5948 5959 10.1074/jbc.M115.700997 26786097 PMC4786728 Moriwaki, K. & Chan, F. K. M. Regulation of RIPK3- and RHIM-dependent necroptosis by the Proteasome. J. Biol. Chem. 291 26786097 10.1074/jbc.M115.700997 PMC4786728 28. Rivas M Gevorgyan V Advances in selected heterocyclization methods Synlett 2023 34 1554 1562 10.1055/s-0042-1751429 37876737 PMC10593425 Rivas, M. & Gevorgyan, V. Advances in selected heterocyclization methods. Synlett 34 37876737 10.1055/s-0042-1751429 PMC10593425 29. Venkateswarlu V Direct N-heterocyclization of hydrazines to access styrylated pyrazoles: synthesis of 1,3,5-trisubstituted pyrazoles and dihydropyrazoles RSC Adv. 2018 8 26523 26527 10.1039/C8RA04550J 35541044 PMC9083136 Venkateswarlu, V. et al. Direct N-heterocyclization of hydrazines to access styrylated pyrazoles: synthesis of 1,3,5-trisubstituted pyrazoles and dihydropyrazoles. RSC Adv. 8 35541044 10.1039/c8ra04550j PMC9083136 30. Dong J ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database J. Cheminform 2018 10 29 10.1186/s13321-018-0283-x 29943074 PMC6020094 Dong, J. et al. ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. J. Cheminform 10 29943074 10.1186/s13321-018-0283-x PMC6020094 31. Eliwa EM Cu(II)-Promoted the Chemical synthesis of New azines-based Naphthalene Scaffold as in vitro potent mushroom tyrosinase inhibitors and evaluation of their antiproliferative activity Polycycl. Aromat. Compd. 2023 43 6018 6045 10.1080/10406638.2022.2112704 Eliwa, E. M. et al. Cu(II)-Promoted the Chemical synthesis of New azines-based Naphthalene Scaffold as in vitro potent mushroom tyrosinase inhibitors and evaluation of their antiproliferative activity. Polycycl. Aromat. Compd. 43 32. Veber DF Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002 45 2615 2623 10.1021/jm020017n 12036371 Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45 12036371 10.1021/jm020017n 33. Miller RR Integrating the impact of Lipophilicity on potency and pharmacokinetic parameters enables the Use of Diverse Chemical Space during small Molecule Drug optimization J. Med. Chem. 2020 63 12156 12170 10.1021/acs.jmedchem.9b01813 32633947 Miller, R. R. et al. Integrating the impact of Lipophilicity on potency and pharmacokinetic parameters enables the Use of Diverse Chemical Space during small Molecule Drug optimization. J. Med. Chem. 63 32633947 10.1021/acs.jmedchem.9b01813 34. Arafeh MM Moghadam ES Adham SAI Stoll R Abdel-Jalil RJ Synthesis and cytotoxic activity study of Novel 2-(Aryldiazenyl)-3-methyl-1H-benzo[g]indole derivatives Molecules 2021 26 4240 10.3390/molecules26144240 34299515 PMC8306180 Arafeh, M. M., Moghadam, E. S., Adham, S. A. I., Stoll, R. & Abdel-Jalil, R. J. Synthesis and cytotoxic activity study of Novel 2-(Aryldiazenyl)-3-methyl-1H-benzo[g]indole derivatives. Molecules 26 34299515 10.3390/molecules26144240 PMC8306180 35. Bartošová A Blinová L Sirotiak M Michalíková A Usage of FTIR-ATR as non-destructive analysis of selected toxic dyes Res. Pap Fac. Mater. Sci. Technol. Slovak Univ. Technol. 2017 25 103 111 Bartošová, A., Blinová, L., Sirotiak, M. & Michalíková, A. Usage of FTIR-ATR as non-destructive analysis of selected toxic dyes. Res. Pap Fac. Mater. Sci. Technol. Slovak Univ. Technol. 25 36. Wadhwa P Kharbanda A Sharma A Thia-Michael Addition: an emerging strategy in Organic synthesis Asian J. Org. Chem. 2018 7 634 661 10.1002/ajoc.201700609 Wadhwa, P., Kharbanda, A. & Sharma, A. Thia-Michael Addition: an emerging strategy in Organic synthesis. Asian J. Org. Chem. 7 37. Yakaiah S Sagar Vijay Kumar P Baby Rani P Durga Prasad K Aparna P Design, synthesis and biological evaluation of novel pyrazolo-oxothiazolidine derivatives as antiproliferative agents against human lung cancer cell line A549 Bioorg. Med. Chem. Lett. 2018 28 630 636 10.1016/j.bmcl.2018.01.027 29395969 Yakaiah, S., Sagar Vijay Kumar, P., Baby Rani, P., Durga Prasad, K. & Aparna, P. Design, synthesis and biological evaluation of novel pyrazolo-oxothiazolidine derivatives as antiproliferative agents against human lung cancer cell line A549. Bioorg. Med. Chem. Lett. 28 29395969 10.1016/j.bmcl.2018.01.027 38. Asghari S Pourshab M Mohseni M Synthesis, characterization, and evaluation of antioxidant and antibacterial activities of novel indole-hydrazono thiazolidinones Monatshefte für Chemie - Chem. Mon 2018 149 2327 2336 10.1007/s00706-018-2292-x Asghari, S., Pourshab, M. & Mohseni, M. Synthesis, characterization, and evaluation of antioxidant and antibacterial activities of novel indole-hydrazono thiazolidinones. Monatshefte für Chemie - Chem. Mon 149 39. Abdou MM Tailoring of novel morpholine-sulphonamide linked thiazole moieties as dual targeting DHFR/DNA gyrase inhibitors: synthesis, antimicrobial and antibiofilm activities, and DFT with molecular modelling studies New. J. Chem. 2024 48 9149 9162 10.1039/D3NJ05774G Abdou, M. M. et al. Tailoring of novel morpholine-sulphonamide linked thiazole moieties as dual targeting DHFR/DNA gyrase inhibitors: synthesis, antimicrobial and antibiofilm activities, and DFT with molecular modelling studies. New. J. Chem. 48 40. Elgammal WE Thiazolation of phenylthiosemicarbazone to access new thiazoles: anticancer activity and molecular docking Future Med. Chem. 2024 16 1219 1237 10.1080/17568919.2024.2342668 38989988 PMC11247539 Elgammal, W. E. et al. Thiazolation of phenylthiosemicarbazone to access new thiazoles: anticancer activity and molecular docking. Future Med. Chem. 16 38989988 10.1080/17568919.2024.2342668 PMC11247539 41. Boulis AG Diverse bioactive metabolites from Penicillium sp. MMA derived from the red sea: structure identification and biological activity studies Arch. Microbiol. 2020 202 1985 1996 10.1007/s00203-020-01923-x 32476047 Boulis, A. G. et al. Diverse bioactive metabolites from Penicillium sp. MMA derived from the red sea: structure identification and biological activity studies. Arch. Microbiol. 202 32476047 10.1007/s00203-020-01923-x 42. Hornbeck V. P. Enzyme-linked immunosorbent assays Curr. Protoc. Immunol. 2015 110 211 2123 10.1002/0471142735.im0201s110 26237010 Hornbeck, V. P. Enzyme-linked immunosorbent assays. Curr. Protoc. Immunol. 110 10.1002/0471142735.im0201s110 26237010 43. Moriwaki K Chan F K.-M RIP3: a molecular switch for necrosis and inflammation Genes Dev. 2013 27 1640 1649 10.1101/gad.223321.113 23913919 PMC3744722 Moriwaki, K., Chan, F. & K.-M RIP3: a molecular switch for necrosis and inflammation. Genes Dev. 27 23913919 10.1101/gad.223321.113 PMC3744722 44. Hsu KC Chen YF Lin SR Yang JM iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis BMC Bioinform. 2011 12 S33 10.1186/1471-2105-12-S1-S33 PMC3044289 21342564 Hsu, K. C., Chen, Y. F., Lin, S. R. & Yang, J. M. iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinform. 12 10.1186/1471-2105-12-S1-S33 PMC3044289 21342564 45. Eliwa EM Metal-free domino amination-knoevenagel condensation approach to access new coumarins as potent nanomolar inhibitors of VEGFR-2 and EGFR Green. Chem. Lett. Rev. 2021 14 578 599 10.1080/17518253.2021.1981462 35821884 PMC9273165 Eliwa, E. M. et al. Metal-free domino amination-knoevenagel condensation approach to access new coumarins as potent nanomolar inhibitors of VEGFR-2 and EGFR. Green. Chem. Lett. Rev. 14 35821884 10.1080/17518253.2021.1981462 PMC9273165 ",
  "metadata": {
    "Title of this paper": "Metal-free domino amination-knoevenagel condensation approach to access new coumarins as potent nanomolar inhibitors of VEGFR-2 and EGFR",
    "Journal it was published in:": "Scientific Reports",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479950/"
  }
}